Skip to content

Sumitovant Biopharma Logo

  • Home
  • Technology
  • Pipeline
  • Our Companies
  • Leadership
    • Leadership Voices
  • News & Events
  • Join Us
  • Contact
  • All
  • Altavant
  • Enzyvant
  • Myovant
  • Spirovant
  • Sumitovant
  • Urovant
  • April 25, 2022Altavant Sciences to Present Data at ISHLT Showing Potency and Distribution of Bronchiolitis Obliterans Candidate, ALTA-2530
  • April 22, 2022Enzyvant Announces Plans to Expand Regenerative Medicine Manufacturing Capabilities
  • March 25, 2022Sumitovant Biopharma and its Portfolio of Companies Announce Milestone Highlights from the Third Quarter of FY2021
  • March 22, 2022Urovant Sciences Announces Publication of New Review of Efficacy and Safety Data for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients in the Journal Therapeutics and Clinical Risk Management
  • March 07, 2022Urovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902
  • March 02, 2022Sumitovant and Enzyvant Appoint Bill Symonds, CEO of Altavant Sciences, as Interim Chief Executive Officer of Enzyvant
  • February 25, 2022Myovant Sciences Receives Positive CHMP Opinion for ORGOVYX® (relugolix) for the Treatment of Advanced Prostate Cancer
  • February 10, 2022Sumitomo Dainippon Pharma and Sumitovant Biopharma Initiate Phase 1 Study on New Drug Candidate for Carbapenem-Resistant Bacterial Infections
  • February 07, 2022Myovant Sciences to Present at Upcoming Investor Conferences
  • January 26, 2022Enzyvant Appoints Johanna Rossell as Chief Commercial Officer
  • 1 2 3 … 21 Next »
  • Careers
  • Terms of Use
  • Privacy Policy

Sumitovant Biopharma, Inc.

151 W. 42nd Street, 15th Floor

New York, NY 10036

info@sumitovant.com

© 2022 Sumitovant Biopharma

Sumitovant is a trademark of Sumitomo Pharma Co., Ltd.